Bristol-Myers Squibb Beats on Both Top and Bottom Lines

Bristol-Myers Squibb (NYS: BMY) reported earnings on Jan. 24. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Bristol-Myers Squibb beat slightly on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue dropped significantly and GAAP earnings per share increased.

Gross margins dropped, operating margins shrank, net margins expanded.

Revenue details
Bristol-Myers Squibb tallied revenue of $4.19 billion. The 12 analysts polled by S&P Capital IQ expected a top line of $4.14 billion on the same basis. GAAP reported sales were 23% lower than the prior-year quarter's $5.45 billion.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.47. The 16 earnings estimates compiled by S&P Capital IQ anticipated $0.43 per share. GAAP EPS of $0.56 for Q4 were 12% higher than the prior-year quarter's $0.50 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 74.3%, 90 basis points worse than the prior-year quarter. Operating margin was 12.2%, 1,720 basis points worse than the prior-year quarter. Net margin was 22.1%, 650 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $3.93 billion. On the bottom line, the average EPS estimate is $0.44.

Next year's average estimate for revenue is $16.59 billion. The average EPS estimate is $1.84.

Investor sentiment
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 1,704 members out of 1,815 rating the stock outperform, and 111 members rating it underperform. Among 505 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 486 give Bristol-Myers Squibb a green thumbs-up, and 19 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Bristol-Myers Squibb is hold, with an average price target of $34.50.

Can your portfolio provide you with enough income to last through retirement? You'll need more than Bristol-Myers Squibb. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.

• Add Bristol-Myers Squibb to My Watchlist.

The article Bristol-Myers Squibb Beats on Both Top and Bottom Lines originally appeared on Fool.com.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. TMFDisclosureHere

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.